Hyman Phelps Rips FDA Over Ranbaxy Exclusivity
The U.S. Food and Drug Administration is harming responsible drugmakers and costing taxpayers massive sums of money by letting Ranbaxy Laboratories Ltd. pursue marketing exclusivity through product approval applications tainted by...To view the full article, register now.
Already a subscriber? Click here to view full article